Marion Dorsch
President bei Atavistik Bio, Inc.
Profil
Derzeit hat Marion Dorsch die Position des Chief Scientific Officer der Blueprint Medicines Corp. inne. In ihrer früheren Karriere war Dr. Dorsch Vice President-Biology bei Agios Pharmaceuticals, Inc. und Director-Cancer Biology bei Sanofi-Aventis France. Dr. Dorsch hat an der Freien Universität Berlin promoviert.
Aktive Positionen von Marion Dorsch
| Unternehmen | Position | Beginn |
|---|---|---|
Atavistik Bio, Inc.
 Atavistik Bio, Inc. BiotechnologyHealth Technology Atavistik Bio, Inc. is a pre-clinical stage biotechnology company located in an undisclosed location. The American company is pioneering a synthetic, scalable approach to identify and harness highly conserved protein-metabolite interactions to revolutionize small molecule drug discovery. The company's advanced data analytics and AI platforms leverage structure-based drug design to engineer novel, highly specific small molecule drugs to activate, inhibit or stabilize targets. The company is led by an experienced management team and advisors, plus a robust investment syndicate, and is positioned to deliver transformational science to ultimately improve patient care. Atavistik Bio was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Bryan E Stuart has been the CEO of the company since 2023. | President | 01.04.2021 |
Ehemalige bekannte Positionen von Marion Dorsch
| Unternehmen | Position | Ende |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Chief Tech/Sci/R&D Officer | 01.03.2021 |
| AGIOS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.11.2016 |
Sanofi-Aventis France SA
 Sanofi-Aventis France SA Medical DistributorsDistribution Services Sanofi-Aventis France engages in wholesale of pharmaceutical products. The company is headquartered in Gentilly, France. | Corporate Officer/Principal | 01.04.2012 |
Ausbildung von Marion Dorsch
| Freie Universität Berlin | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Sanofi-Aventis France SA
Sanofi-Aventis France SA Medical DistributorsDistribution Services Sanofi-Aventis France engages in wholesale of pharmaceutical products. The company is headquartered in Gentilly, France. | Distribution Services |
Atavistik Bio, Inc.
Atavistik Bio, Inc. BiotechnologyHealth Technology Atavistik Bio, Inc. is a pre-clinical stage biotechnology company located in an undisclosed location. The American company is pioneering a synthetic, scalable approach to identify and harness highly conserved protein-metabolite interactions to revolutionize small molecule drug discovery. The company's advanced data analytics and AI platforms leverage structure-based drug design to engineer novel, highly specific small molecule drugs to activate, inhibit or stabilize targets. The company is led by an experienced management team and advisors, plus a robust investment syndicate, and is positioned to deliver transformational science to ultimately improve patient care. Atavistik Bio was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Bryan E Stuart has been the CEO of the company since 2023. | Health Technology |
